[
    [
        {
            "time": "",
            "original_text": "[强推评级]凯莱英(002821)半年报点评：业绩继续高速增长 继续看好公司长期发展",
            "features": {
                "keywords": [
                    "凯莱英",
                    "半年报",
                    "业绩",
                    "高速增长",
                    "长期发展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强推评级]凯莱英(002821)半年报点评：业绩继续高速增长 继续看好公司长期发展",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[强烈推荐评级]凯莱英(002821)中报点评：扣非业绩54.83%内生高增速超预期 把握机遇几大战略持续推进",
            "features": {
                "keywords": [
                    "凯莱英",
                    "中报",
                    "扣非业绩",
                    "54.83%",
                    "内生增长",
                    "战略推进"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强烈推荐评级]凯莱英(002821)中报点评：扣非业绩54.83%内生高增速超预期 把握机遇几大战略持续推进",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "[买入评级]深度*公司*凯莱英(002821)中报点评：乘行业东风快速增长 打造CDMO一站式服务龙头",
            "features": {
                "keywords": [
                    "凯莱英",
                    "中报",
                    "行业东风",
                    "快速增长",
                    "CDMO",
                    "一站式服务",
                    "龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]深度*公司*凯莱英(002821)中报点评：乘行业东风快速增长 打造CDMO一站式服务龙头",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "加码国际业务 凯莱英再谋港股上市",
            "features": {
                "keywords": [
                    "凯莱英",
                    "国际业务",
                    "港股上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "加码国际业务 凯莱英再谋港股上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "生物医药行业周报:疫苗事件处理结果引发市场担忧 继续推荐细分领域龙头",
            "features": {
                "keywords": [
                    "生物医药",
                    "疫苗事件",
                    "市场担忧",
                    "细分领域龙头"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "生物医药行业周报:疫苗事件处理结果引发市场担忧 继续推荐细分领域龙头",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]